Compile Data Set for Download or QSAR
Report error Found 706 Enz. Inhib. hit(s) with all data for entry = 9360
TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460887(US10774053, Compound 1 | US11352329, COMPD # 1)
Affinity DataEC50:  64.6nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460888(US10774053, Compound 2 | US11352329, COMPD # 2)
Affinity DataEC50:  3.00E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460889(US10774053, Compound 3 | US11352329, COMPD # 3)
Affinity DataEC50:  5.71E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460890(US10774053, Compound 4 | US11352329, COMPD # 4)
Affinity DataEC50:  3.62E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460891(US10774053, Compound 5 | US11352329, COMPD # 5)
Affinity DataEC50:  5.71E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460892(US10774053, Compound 6 | US11352329, COMPD # 6)
Affinity DataEC50:  5.71E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460893(US10774053, Compound 7 | US11352329, COMPD # 7)
Affinity DataEC50:  5.71E+4nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460894(US10774053, Compound 8 | US11352329, COMPD # 8)
Affinity DataEC50:  277nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460895(US10774053, Compound 9 | US11352329, COMPD # 9)
Affinity DataEC50:  1.69E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460896(US10774053, Compound 10 | US11352329, COMPD # 10)
Affinity DataEC50:  91.9nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460897(US10774053, Compound 11)
Affinity DataEC50:  35.5nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460898(US10774053, Compound 12 | US11352329, COMPD # 12)
Affinity DataEC50:  22.2nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460899(US10774053, Compound 13 | US11352329, COMPD # 13)
Affinity DataEC50:  310nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460900(US10774053, Compound 14 | US11352329, COMPD # 14)
Affinity DataEC50:  68.6nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460901(US10774053, Compound 15 | US11352329, COMPD # 15)
Affinity DataEC50:  230nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460902(US10774053, Compound 16 | US11352329, COMPD # 16)
Affinity DataEC50:  11.4nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460903(US10774053, Compound 17)
Affinity DataEC50:  556nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460904(US10774053, Compound 18 | US11352329, COMPD # 18)
Affinity DataEC50:  9.56nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460905(US10774053, Compound 19 | US11352329, COMPD # 19)
Affinity DataEC50:  49.9nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460906(US10774053, Compound 20 | US11352329, COMPD # 20)
Affinity DataEC50:  76.7nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460907(US10774053, Compound 21 | US11352329, COMPD # 21)
Affinity DataEC50:  63.8nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460909(US10774053, Compound 23 | US11352329, COMPD # 23)
Affinity DataEC50:  70.4nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460910(US10774053, Compound 24 | US11352329, COMPD # 24)
Affinity DataEC50:  68.2nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460911(US10774053, Compound 25 | US11352329, COMPD # 25)
Affinity DataEC50:  52.7nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460912(US10774053, Compound 26 | US11352329, COMPD # 27)
Affinity DataEC50:  102nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460913(US10774053, Compound 27)
Affinity DataEC50:  80.4nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460914(US10774053, Compound 28)
Affinity DataEC50:  91.7nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460915(US10774053, Compound 29 | US11352329, COMPD # 29)
Affinity DataEC50:  228nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460916(US10774053, Compound 30 | US11352329, COMPD # 30)
Affinity DataEC50:  120nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460917(BDBM556558 | US10774053, Compound 31)
Affinity DataEC50:  51nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460918(US10774053, Compound 32 | US11352329, COMPD # 32)
Affinity DataEC50:  69.2nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460919(US10774053, Compound 33 | US11352329, COMPD # 33)
Affinity DataEC50:  37.2nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460920(US10774053, Compound 34 | US11352329, COMPD # 34)
Affinity DataEC50:  38.7nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460921(US10774053, Compound 35 | US11352329, COMPD # 35)
Affinity DataEC50:  98.1nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460922(US10774053, Compound 36 | US11352329, COMPD # 36)
Affinity DataEC50:  89.3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460923(US10774053, Compound 37 | US11352329, COMPD # 37)
Affinity DataEC50:  219nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460924(US10774053, Compound 38 | US11352329, COMPD # 38)
Affinity DataEC50:  9.83nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460925(US10774053, Compound 39 | US11352329, COMPD # 39)
Affinity DataEC50:  29.8nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460926(US10774053, Compound 40 | US11352329, COMPD # 40)
Affinity DataEC50:  84.1nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460927(US10774053, Compound 41 | US11352329, COMPD # 41)
Affinity DataEC50:  18.1nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460928(US10774053, Compound 42 | US11352329, COMPD # 42)
Affinity DataEC50:  103nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460930(US10774053, Compound 43 | US11352329, COMPD # 43)
Affinity DataEC50:  8.18nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460931(US10774053, Compound 44 | US11352329, COMPD # 44)
Affinity DataEC50:  246nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460932(US10774053, Compound 45 | US11352329, COMPD # 45)
Affinity DataEC50:  31.7nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460933(US10774053, Compound 46 | US11352329, COMPD # 46)
Affinity DataEC50:  37.6nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460934(US10774053, Compound 47 | US11352329, COMPD # 47)
Affinity DataEC50:  60.9nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460935(US10774053, Compound 48 | US11352329, COMPD # 48)
Affinity DataEC50:  80nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460936(US10774053, Compound 49 | US11352329, COMPD # 49)
Affinity DataEC50:  68.1nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460937(US10774053, Compound 50 | US11352329, COMPD # 50)
Affinity DataEC50:  27.7nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Gilead Sciences

US Patent
LigandPNGBDBM460938(US10774053, Compound 51 | US11352329, COMPD # 51)
Affinity DataEC50:  33.6nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 706 total ) | Next | Last >>
Jump to: